| Expression pattern: |
UP |
| Associated gene: |
MEF2A, MCL1 |
| Associated microRNA: |
miR-455-3p |
| Biological function: |
promotes cell viability and EMT; inhibits apoptosis; promotes malignant progression of AML cells |
| Molecular mechanism: |
MEF2A acts as a transcription factor increasing circPVT1 promoter activity; circPVT1 acts as a ceRNA/miRNA sponge for miR-455-3p to upregulate MCL1 |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); EMT (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; RNase R Treatment; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); Transfection; CCK8; Annexin V/PI Flow Cytometry; Western Blot; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
circPVT1 could be considered a diagnostic biomarker or a molecular therapeutic target for AML |
| Description: |
circPVT1 is up-regulated in AML plasma and AML cell lines. MEF2A increases circPVT1 expression via promoter activation, and circPVT1 promotes AML cell viability and EMT and suppresses apoptosis by sponging miR-455-3p to upregulate MCL1. |
| Confidence score: |
0.7551 |